CONTACT
DIAGNOSTICS
ABOUT ABBOTT
i-STAT REGISTRATION
i-STAT LOGIN
CUSTOMER HOME
PARTNERS HOME
DISTRIBUTION HOME
EMPLOYEES HOME
REPAIR MANUAL
COMPLETE PROFILE
DASHBOARD
My Account
United Kingdom

Global Point of Care

ID NOW™ provides actionable results exactly when and where they are needed

ID NOW is a rapid, respiratory molecular testing platform that delivers accurate results in just minutes, so you can make diagnostic decisions during the first patient visit. ID NOW provides diagnostic results where and when you need them — in near-patient settings at the point of care.

Get in touch today to learn more about how you can improve your workflow and potentially save costs with the ID NOW platform and available tests
Get in touch
image
image
Get in touch today to learn more about how you can improve your workflow and potentially save costs with the ID NOW platform and available tests
Get in touch
imaged
imaged

designed to meet the need for immediate decision making without compromising quality

The ID NOW Platform allows lab directors to maintain high diagnostic quality, while empowering clinicians to make faster decisions with diagnostic results in real time.

flexible diagnostics flexible diagnostics flexible diagnostics

flexible diagnostic testing for better clinical outcomes

With ID NOW you can test for COVID-19, influenza, RSV, and strep A on one platform. With the platform's flexibility, you can base your testing on prevalence and other available clinical parameters, which allows you to eliminate unnecessary tests and thereby achieve increased testing accuracy and clinical certainty.

enhanced-flexibility icon enhanced-flexibility icon enhanced-flexibility icon

enhanced flexibility for covid-19 and flu testing

The ID NOW Platform gives you the flexibility to test for COVID-19 only or test for COVID-19 and influenza A & B using a single patient swab. With positive COVID-19 results in as few as 6 minutes, or results for both COVID-19 and influenza A & B within 15 – 22 minutes, ID NOW improves patient management and helps control the spread of disease.

rt-pcr icon rt-pcr icon rt-pcr icon

RT-pcr equivalent results for better PATiENT MANAGEMENT

ID NOW is the fastest rapid molecular solution available, with accurate positive results in 6 minutes or faster.1 Using rapid nucleic acid amplification technology (NAAT), it offers RT-PCR equivalent results in real-time, without compromising quality—giving you immediate answers to make patient management decisions in the moment.

id now icon id now icon id now icon

designed for intuitive use and on-DEMAND TESTING

Testing with the ID NOW Platform is designed for intuitive use and supported by on-screen guidance at every step, requiring minimal training to operate the platform. Plus, the assay kits contain all the components you need without requiring refrigeration, so you can test on demand right out of the box when and where needed.

reliably connected icon reliably connected icon reliably connected icon

reliably connected for automated reporting

ID NOW connects seamlessly to existing patient data management infrastructure to reliably connect the diagnostic and patient management pathways, improving workflows.

presentation presentation presentation

Watch the Technology Video

Using nucleic acid amplification technology (NAAT), ID NOW is the fastest rapid molecular solution available, offering real-time RT-PCR equivalent results, without compromising quality. Get accurate results in 6 minutes or faster.1 

WATCH THE VIDEO
image

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines also recommend rapid molecular (nucleic acid amplification testing, or NAAT) testing for COVID-19 whenever speed to result, patient outcome and early isolation are of importance.2

idnoweme2022
idnoweme2022
idnoweme2022
id now id now id now

available tests for the id NOW PLATFORM

COVID-19 2.0
influenza A & B 2
RSV
Strep A 2

take the next steps in achieving real‑TIME DIAGNOSTICS

Get in Touch

References

  1. ID NOW provides negative results in 12 minutes for COVID-19, 13 minutes for influenza A & B or RSV, and 8 minutes for strep A. Positive results are provided within 13 minutes for RSV and as fast as 6 minutes for COVID-19, 5 minutes for influenza A & B or 2 minutes for strep A.
  2. Fragkou PC, De Angelis G, Menchinelli G, et al. ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2. Clin Microbiol Infect. 2022;28(6):812-822.
    doi:10.1016/i.cmi.2022.02.011

©2023 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.

Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy: US Citizens | Non-US Citizens. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement (last updated: May 2018) | California Transparency in Supply Chains Act | Declaration for California Compliance Law.

Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.

Abbott - A Leader in Rapid Point-of-Care Diagnostics.